NYSE: PFE | Healthcare / Drug Manufacturers / USA |
38.97 | -0.1200 | -0.31% | Vol 19.69M | 1Y Perf -24.51% |
Jun 9th, 2023 16:03 DELAYED |
BID | 38.94 | ASK | 38.98 | ||
Open | 39.28 | Previous Close | 38.97 | ||
Pre-Market | - | After-Market | 39.01 | ||
- - | 0.04 0.10% |
Target Price | 57.40 | Analyst Rating | Moderate Buy 2.20 | |
Potential % | 47.29 | Finscreener Ranking | ★★★+ 51.81 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 53.95 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★★ 68.88 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★★★★ 50.71 | |
Price Range Ratio 52W % | 14.93 | Earnings Rating | Neutral | |
Market Cap | 220.00B | Earnings Date | 27th Jul 2023 | |
Alpha | 0.00 | Standard Deviation | 0.08 | |
Beta | 0.64 |
Today's Price Range 38.8739.59 | 52W Range 36.1754.93 | 5 Year PE Ratio Range 8.9036.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 1.59% | ||
1 Month | 1.75% | ||
3 Months | -1.07% | ||
6 Months | -24.65% | ||
1 Year | -24.51% | ||
3 Years | 16.83% | ||
5 Years | 6.27% | ||
10 Years | 49.29% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 14.43 | |||
ROE last 12 Months | 37.98 | |||
ROA (5Y Avg) | 5.45 | |||
ROA last 12 Months | 17.15 | |||
ROC (5Y Avg) | 12.08 | |||
ROC last 12 Months | 25.39 | |||
Return on invested Capital Q | 6.94 | |||
Return on invested Capital Y | 3.17 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 4.70 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.80 | ||||
3.09 | ||||
3.57 | ||||
11.00 | ||||
52.10 | ||||
4.64 | ||||
19.00 | ||||
16.50 | ||||
310.83B | ||||
Forward PE | 11.60 | |||
PEG | 1.09 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.20 | ||||
1.60 | ||||
0.25 | ||||
0.39 | ||||
27.90 | ||||
Leverage Ratio | 2.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
65.50 | ||||
34.60 | ||||
39.50 | ||||
9.70 | ||||
34.72 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
76.04B | ||||
13.55 | ||||
14.63 | ||||
6.29 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.39 | ||||
1.64 | ||||
3.87 | ||||
5.00 | ||||
Payout ratio | 92.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2023 | 1.00 | 1.23 | 23.00 |
Q04 2022 | 1.03 | 1.14 | 10.68 |
Q03 2022 | 1.47 | 1.78 | 21.09 |
Q02 2022 | 1.75 | 2.04 | 16.57 |
Q01 2022 | 1.66 | 1.62 | -2.41 |
Q04 2021 | 0.85 | 1.08 | 27.06 |
Q03 2021 | 1.08 | 1.34 | 24.07 |
Q02 2021 | 0.97 | 1.07 | 10.31 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2023 QR | 0.63 | -4.55 | Negative |
9/2023 QR | 0.69 | -19.77 | Negative |
12/2023 FY | 3.35 | 0.60 | Positive |
12/2024 FY | 3.33 | -13.95 | Negative |
Next Report Date | 27th Jul 2023 |
Estimated EPS Next Report | 0.63 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | 9.00 |
Volume Overview | |
---|---|
Volume | 19.69M |
Shares Outstanding | 5.65M |
Shares Float | 5.61B |
Trades Count | 139.97K |
Dollar Volume | 770.21M |
Avg. Volume | 24.15M |
Avg. Weekly Volume | 20.24M |
Avg. Monthly Volume | 28.47M |
Avg. Quarterly Volume | 23.74M |
Pfizer Inc. (NYSE: PFE) stock closed at 38.97 per share at the end of the most recent trading day (a -0.31% change compared to the prior day closing price) with a volume of 19.69M shares and market capitalization of 220.00B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 78500 people. Pfizer Inc. CEO is Albert Bourla.
The one-year performance of Pfizer Inc. stock is -24.51%, while year-to-date (YTD) performance is -23.95%. PFE stock has a five-year performance of 6.27%. Its 52-week range is between 36.17 and 54.93, which gives PFE stock a 52-week price range ratio of 14.93%
Pfizer Inc. currently has a PE ratio of 9.80, a price-to-book (PB) ratio of 3.09, a price-to-sale (PS) ratio of 3.57, a price to cashflow ratio of 11.00, a PEG ratio of 2.32, a ROA of 17.15%, a ROC of 25.39% and a ROE of 37.98%. The company’s profit margin is 34.72%, its EBITDA margin is 39.50%, and its revenue ttm is $76.04 Billion , which makes it $13.55 revenue per share.
Of the last four earnings reports from Pfizer Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.63 for the next earnings report. Pfizer Inc.’s next earnings report date is 27th Jul 2023.
The consensus rating of Wall Street analysts for Pfizer Inc. is Moderate Buy (2.2), with a target price of $57.4, which is +47.29% compared to the current price. The earnings rating for Pfizer Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Pfizer Inc. has a dividend yield of 3.39% with a dividend per share of $1.64 and a payout ratio of 92.00%.
Pfizer Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 6.45, ATR14 : 0.81, CCI20 : 108.02, Chaikin Money Flow : 0.03, MACD : 0.00, Money Flow Index : 71.16, ROC : -1.69, RSI : 54.49, STOCH (14,3) : 65.49, STOCH RSI : 0.86, UO : 50.07, Williams %R : -34.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Pfizer Inc. in the last 12-months were: Albert Bourla (Option Excercise at a value of $6 058 579), Angela Hwang (Option Excercise at a value of $464 049), Douglas M. Lankler (Option Excercise at a value of $2 672 547), Hwang Angela (Option Excercise at a value of $1 720 655), Jennifer B. Damico (Option Excercise at a value of $570 681), Jennifer B. Damico (Sold 9 912 shares of value $396 678 ), Johnson Rady (Option Excercise at a value of $1 722 445), Michael McDermott (Option Excercise at a value of $324 534), Mikael Dolsten (Option Excercise at a value of $2 627 259), Payal Sahni (Option Excercise at a value of $204 202), Rady A. Johnson (Option Excercise at a value of $770 340), Sahni Payal (Option Excercise at a value of $663 057), Sally Susman (Option Excercise at a value of $1 670 603), Susman Sally (Option Excercise at a value of $3 964 820)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
CEO: Albert Bourla
Telephone: +1 212 733-2323
Address: 235 East 42nd Street, New York 10017, NY, US
Number of employees: 78 500
Wed, 07 Jun 2023 09:55 GMT Pfizer (PFE) Receives a Hold from SVB Securities
- TipRanks. All rights reserved.Wed, 03 May 2023 11:01 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Sarepta Therapeutics (SRPT) and Rhythm Pharmaceuticals (RYTM)
- TipRanks. All rights reserved.Tue, 02 May 2023 13:00 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Harmony Biosciences Holdings (HRMY)
- TipRanks. All rights reserved.Fri, 07 Apr 2023 06:50 GMT Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), NeoGenomics (NEO) and Pharvaris (PHVS)
- TipRanks. All rights reserved.Mon, 06 Mar 2023 08:35 GMT Pfizer (PFE) Receives a Hold from Jefferies
- TipRanks. All rights reserved.Wed, 01 Feb 2023 14:05 GMT Pfizer (PFE) Gets a Buy from BMO Capital
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.